The signing of this acquisition cooperation is undoubtedly an important development opportunity for both Zybio and Shenzhen Thistory Bio-Medical Company.

Quest Diagnostics has introduced two Post-COVID-19 panels for consumers that offer information about lingering health issues associated with previous COVID-19 virus infections.

According to Kalorama Information, the U.S. IVD market reached $53 billion in 2022, or approximately 40% to 45% of the global market. Projected growth is 2.4% annually on average through 2027.

Bio-economy is a new economic form based on the development progress and popular application of life science and biotechnology, and is an important part of the national economy.

Supplies of laboratory reagents, testing components and transport media are expected to normalize in the first half of 2023, ending shortages that date back to early in the pandemic, according to the Food and Drug Administration.

BostonGene said on Wednesday that it is collaborating with the Little Warrior Foundation to develop liquid biopsy assays for the detection of sarcoma-related molecular alterations and gene fusions.

Which segmentations will have a broader development prospect in the Chinese IVD field?

Roche said Wednesday that it has entered a collaboration with drug maker Eli Lilly to support development of Roche's Elecsys Amyloid Plasma Panel (EAPP), a blood test for aiding earlier diagnosis of Alzheimer's disease.

Genomadix announced on Wednesday that the US Food and Drug Administration has granted 510(k) clearance to its automated sample-to-result Genomadix Cube PCR system and CYP2C19 test.

On March 21, according to the Qichacha data, the major shareholders of Shenzhen Thistory Bio-Medical Company have been changed from Shenzhen Thistory Bio-medical Management and Consulting Enterprise to Zybio Inc.

Researchers in Spain have evaluated a minimally invasive test based on dried blood spot samples for hepatitis C RNA detection and genotyping.

Point-of-care diagnostics firm LumiraDx on Tuesday reported a 65 percent decrease in its fourth quarter revenues.

In March 2023, Cygnus received another round of Series C+ financing of hundreds of millions of RMB, led by Source Capital, and followed by Jianxin Equity, Yizhuang State Investment, Fangzhenghesheng, and Hetang Venture Capital.

DiaSorin said late Friday that it has nabbed US Food and Drug Administration 510(k) clearance for a molecular assay that differentiates between infections with the SARS-CoV-2 and influenza A and B viruses.

Cue Health announced on Monday that it has received Emergency Use Authorization from the US Food and Drug Administration for its molecular monkeypox test.